These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28854317)

  • 1. Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases.
    Houriet C; Seyed Jafari SM; Thomi R; Schlapbach C; Borradori L; Yawalkar N; Hunger RE
    JAMA Dermatol; 2017 Nov; 153(11):1195-1197. PubMed ID: 28854317
    [No Abstract]   [Full Text] [Related]  

  • 2. Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.
    Tekin B; Salman A; Ergun T
    Indian J Dermatol Venereol Leprol; 2017; 83(5):615-617. PubMed ID: 28731016
    [No Abstract]   [Full Text] [Related]  

  • 3. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.
    Casseres RG; Kahn JS; Her MJ; Rosmarin D
    J Am Acad Dermatol; 2019 Jul; 81(1):265-267. PubMed ID: 30562567
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
    Alecsandru D; Padilla B; Izquierdo JA; Fernández-Cruz E; Sánchez-Ramón S
    Arch Dermatol; 2010 Dec; 146(12):1343-5. PubMed ID: 21173317
    [No Abstract]   [Full Text] [Related]  

  • 5. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
    Moul DK; Korman NJ
    Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab for the treatment of hidradenitis suppurativa.
    Fernández-Vozmediano JM; Armario-Hita JC
    Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
    Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
    Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
    [No Abstract]   [Full Text] [Related]  

  • 8. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
    Prussick L; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Abdat R; Alomran A; Zancanaro P; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    Br J Dermatol; 2019 Sep; 181(3):609-611. PubMed ID: 30801662
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.
    Ghias MH; Johnston AD; Kutner AJ; Micheletti RG; Hosgood HD; Cohen SR
    J Am Acad Dermatol; 2020 May; 82(5):1094-1101. PubMed ID: 31589948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.
    Weber P; Seyed Jafari SM; Yawalkar N; Hunger RE
    J Am Acad Dermatol; 2017 Jun; 76(6):1189-1191. PubMed ID: 28522043
    [No Abstract]   [Full Text] [Related]  

  • 13. Moderate to severe hidradenitis suppurativa treated with biological therapies.
    Chinniah N; Cains GD
    Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
    Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
    J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hidradenitis suppurativa is treated with low-dose flutamide.
    Li C; Xu H; Zhang X; Zhang W; He Y; Wang B
    J Dermatol; 2019 Feb; 46(2):e52-e54. PubMed ID: 30076633
    [No Abstract]   [Full Text] [Related]  

  • 16. Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa.
    Russo V; Alikhan A
    J Drugs Dermatol; 2016 Jun; 15(6):772-4. PubMed ID: 27272089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1β).
    Jaeger T; Andres C; Grosber M; Zirbs M; Hein R; Ring J; Traidl-Hoffmann C
    Eur J Dermatol; 2013; 23(3):408-10. PubMed ID: 23816498
    [No Abstract]   [Full Text] [Related]  

  • 19. Guselkumab in the treatment of severe hidradenitis suppurativa.
    Kovacs M; Podda M
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e140-e141. PubMed ID: 30480844
    [No Abstract]   [Full Text] [Related]  

  • 20. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
    Gulliver WP; Jemec GB; Baker KA
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.